Author： Muhamad Aly Rifai Loftis Jennifer M. Hauser Peter
Publisher： Adis International
ISSN： 1172-7047
Source： CNS Drugs, Vol.19, Iss.8, 2005-01, pp. : 719-721
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
A Risk-Benefit Assessment of Sildenafil in the Treatment of Erectile Dysfunction
By Vitezic D.
Drug Safety, Vol. 24, Iss. 4, 2001-01 ,pp. :
Access to resources
Recommend
A Risk-Benefit Assessment of Alendronate in the Treatment of Involutional Osteoporosis
Drug Safety, Vol. 19, Iss. 2, 1998-08 ,pp. :
A Risk-Benefit Assessment of Treatment with Finasteride in Benign Prostatic Hyperplasia
By Ekman P.
Drug Safety, Vol. 18, Iss. 3, 1998-03 ,pp. :